Moderna, Inc.

NASDAQ:MRNA

Biotechnology

Healthcare
$196.79 +4.01%

+$2.48 today

Market cap
$79.63B
Beta
1.03
P/E (TTM)
-7.9
EPS (TTM)
-$8.09
52W Low $22.28High $67.74

Volume 6.91M

Average 6.53M

MRNA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Moderna, Inc.NASDAQ: MRNA

Gross Margin · Q3 FY2026 · quarter ended Sep 2026

Gross margin widens to 75.8%

Gross margin was 75.8% in Q3 FY2026, up 75.0 pp from a year earlier. On a trailing-twelve-month basis it was 28.0%, up 16.1 pp year over year. Over 3 fiscal years it narrowed by 16.0 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
75.8%+39.9 pp QoQ
Last fiscal yearDec 2025
55.3%+1.1 pp YoY
LTMSep 2026
28.0%+16.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+75.0 pp——
1 year+1.1 pp——
3 years-16.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
55.3%
Year-over-year change
+1.1pp

Gross Margin vs competitors

How MRNA compares with its peers on the latest reported figures

  • MRNA's LTM Sep 2026 gross margin of 28.0% is the lowest of the 9 companies compared; the peer median is 78.9%.
  • Its year-over-year change of +16.1 pp is the 2nd highest of 9, against a peer median of -1.4 pp.
  • Over three fiscal years its change of -16.0 pp compares with a peer median of +6.6 pp.
MRNA Competitors Peer median
Gross Margin for MRNA and competitors
Company Period LTM level YoY 3-year change
VIRVir Biotechnology, Inc.LTM Mar 2026275.2% +2604.6 pp+21.4 pp
INOInovio Pharmaceuticals, Inc.FY2025100.0% +0.0 pp+0.0 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202691.2% -8.8 pp-4.5 pp
NVAXNovavax, Inc.LTM Mar 202684.6% -2.8 pp+50.1 pp
PFEPfizer Inc.LTM Jun 202673.2% +1.1 pp+8.3 pp
GSKGSK plcLTM Jun 202672.7% +1.4 pp+5.0 pp
BNTXBioNTech SELTM Jun 202670.8% -8.9 pp-5.1 pp
VALNValneva SELTM Mar 202629.5% -17.1 pp+28.5 pp
MRNAModerna, Inc.LTM Sep 202628.0% +16.1 pp-16.0 pp
PCVXVaxcyte, Inc.FY2025— ——
Peer median (excluding MRNA) 78.9%-1.4 pp+6.6 pp

Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.74B18.88B6.85B3.2B1.94B
Cost of Revenue2.62B5.42B4.69B1.46B868M
Gross Profit15.12B13.46B2.16B1.74B1.08B
Gross Margin85.2%71.3%31.5%54.2%55.3%
Research & Development1.99B3.3B4.85B4.54B3.13B
Selling, General & Admin567M1.13B1.55B1.17B1.02B
Operating Expenses1.82B4.04B6.39B5.68B4.15B
Depreciation & Amortization232M348M621M189M215M
EBITDA13.54B9.95B(3.28B)(3.39B)(2.55B)
EBITDA Margin76.3%52.7%-47.9%-106.1%-131.3%
Operating Income13.3B9.42B(4.24B)(3.95B)(3.07B)
Operating Margin75.0%49.9%-61.9%-123.3%-158.1%
Interest Income18M200M421M425M314M
Interest Expense18M29M38M24M10M
Other Income / Expenses(11M)155M297M338M306M
Income Before Tax13.29B9.58B(3.94B)(3.61B)(2.77B)
Pre-Tax Margin74.9%50.7%-57.6%-112.8%-142.4%
Income Tax Expense1.08B1.21B772M(46M)54M
Net Income12.2B8.36B(4.71B)(3.56B)(2.82B)
Net Margin68.8%44.3%-68.8%-111.3%-145.2%
EPS (Basic)30.3121.26(12.34)(9.27)(7.26)
EPS (Diluted)28.2920.10(12.34)(9.27)(7.26)
Weighted Avg Shares403M394M382M384M389M
Weighted Avg Shares (Diluted)431M416M382M384M389M

Moderna, Inc.

NASDAQ:MRNA

Intrinsic Alpha fair value

Locked

Current Price

$196.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.